Back

Effect of apolipoprotein B reduction on major adverse cardiovascular events in randomized controlled trials of triglyceride-lowering therapies: systematic review and exploratory meta-regression

30 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Lipid lowering and cardiovascular outcomes Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Miguel Sobral Domingues

Western Lisbon Hospital Centre, EPE, Lisbon (Portugal)

6 More presentations in this session

Presentation thumbnail
Gender-related differences in efficacy, safety and adherence of PCSK9 inhibitors in real-world clinical practice: insights from the AT-TARGET-IT Registry
Professor P. Perrone-Filardi (Naples, IT)
Abstract
Presentation thumbnail
Sustained combination lipid-lowering therapy determines durability of LDL-C <55 mg/dL after ACS: a structured implementation study (2022–2026)
Doctor K. Mahajan (Mandi, IN)
Abstract
Presentation thumbnail
EDP167, an ANGPTL3-target siRNA, showed favorable safety and lipid-lowering potential in Chinese healthy adult volunteers and subjects with mild dyslipidemia
Doctor B. Jiang (Hangzhou, CN)
Abstract
Presentation thumbnail
Statin therapy and 1-year mortality in non-ischaemic acute myocardial injury: a dual-cohort study
Doctor T. Yang (Tianjin, CN)
Abstract
Presentation thumbnail
Pooled on treatment lipid lowering efficacy of the CETP inhibitor obicetrapib in phase III trials
Mr M. De Kleer (Amsterdam, NL)
Abstract

Access the full session

Session thumbnail
Lipid lowering and cardiovascular outcomes

The Event

Event poster

ESC Congress 2026

30 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Icosapent ethyl reduces cardiovascular risk across apolipoprotein b and fasting triglyceride rich lipoprotein levels
30 August 2025
thumbnail
Congress Presentation
Apolipoprotein B and cardiovascular risk in asymptomatic patients: need for systematic evaluation?
14 April 2023
thumbnail
Congress Presentation
Non-statin lipid-lowering therapy in coronary atherosclerosis regression: A meta-analysis and meta-regression.
30 August 2020
thumbnail
Congress Presentation
Insights into the reporting of major adverse cardiovascular events in coronary artery disease trials
30 August 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources